HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fisher, M. Articles by McGehee, W. Search for Related Content PubMed PubMed Citation Articles by Fisher, M. Articles by McGehee, W.

Cerebral infarct, TIA, and lupus inhibitor

Departments of Neurology (Dr. Fisher) and Medicine (Dr. McGehee), University of Southern California School of Medicine, Los Angeles, CA.

A lupus inhibitor paradoxically prolongs phospholipid-dependent coagulation assays, but may increase risk of thromboembolism. We studied seven patients with cerebral infarcts and one with TIA who had lupus inhibitor. The average age at onset of cerebral ischemia was 41 years. Three patients had multiple cerebral ischemic events. The activated partial thromboplastin time was longer than that of controls, but usually within normal limits. Other abnormalities included biologic false-positive VDRL, antinuclear antibodies, thrombocytopenia (three patients each), and deep vein thrombosis (two patients).

Address correspondence and reprint requests to Dr. Fisher, Department of Neurology, Unit I, Room 5641, USC School of Medicine, 1200 North State Street, Los Angeles, CA 90033.

Supported in part by NINCDS 5 R01 NS20989–02. Dr. Fisher is recipient of Teacher Investigator Development Award 5 K07NS00884–02.

Presented in part at the thirty-seventh meeting of the American Academy of Neurology, Dallas, TX, April 28-May 4, 1985.

Accepted for publication January 28, 1986.

This article has been cited by other articles:

				N-S Lai and J-L Lan Evaluation of cerebrospinal anticardiolipin antibodies in lupus patients with neuropsychiatric manifestations Lupus, June 1, 2000; 9(5): 353 - 357. [Abstract] [PDF]

				H. Nomura, Y. Hirashima, S. Endo, A. Takaku, and R. L. Macdonald Anticardiolipin Antibody Aggravates Cerebral Vasospasm After Subarachnoid Hemorrhage in Rabbits • Editorial Comment Stroke, May 1, 1998; 29(5): 1014 - 1019. [Abstract] [Full Text] [PDF]

				R. L. Brey Stroke Prevention in Patients with Antiphospholipid Antibodies Lupus, August 1, 1994; 3(4): 299 - 302. [PDF]

				G. Rivier, M. T. Herranz, M. A. Khamashta, and G. R.V. Hughes Thrombosis and Antiphospholipid Syndrome: a Preliminary Assessment of Three Antithrombotic Treatments Lupus, April 1, 1994; 3(2): 85 - 90. [Abstract] [PDF]

				P. E. Love and S. A. Santoro Antiphospholipid Antibodies: Anticardiolipin and the Lupus Anticoagulant in Systemic Lupus Erythematosus (SLE) and in Non-SLE Disorders: Prevalence and Clinical Significance Ann Intern Med, May 1, 1990; 112(9): 682 - 698. [Abstract] [PDF]

				D. A. Triplett, J. T. Brandt, K. A. Musgrave, and C. A. Orr The Relationship Between Lupus Anticoagulants and Antibodies to Phospholipid JAMA, January 22, 1988; 259(4): 550 - 554. [Abstract] [PDF]

				S. R. Levine and K. M. A. Welch The Spectrum of Neurologic Disease Associated With Antiphospholipid Antibodies: Lupus Anticoagulants and Anticardiolipin Antibodies Arch Neurol, August 1, 1987; 44(8): 876 - 883. [Abstract] [PDF]

				S. A. Lipton and N. F. Schor Lupus Anticoagulant and Stroke-Reply Arch Neurol, July 1, 1987; 44(7): 691 - 692. [Abstract] [PDF]